Medication Compliance Research Articles

Quality of life, effectiveness, and compliance of fruquintinib in the treatment of metastatic colorectal cancer: Results from a prospective real-world study.

e15557 Background: Fruquintinib, an antiangiogenic tyrosine kinase inhibitor (TKI), has demonstrated its significant survival benefits in metastatic colorectal cancer (mCRC) patients in both China and global phase III trials (FRESCO and FRESCO-2), but data on patients' health-related quality of life (HRQoL) was rare. A previous study on HRQoL of mCRC patients receiving another antiangiogenic TKI or placebo showed a decreased pattern in the mean utility index (UI) score of EuroQol 5-dimension (EQ-5D). This study intended to evaluate the HRQoL of mCRC patients receiving fruquintinib in the real world and describe its real-world treatment outcomes and compliance. Methods: This is a multicenter prospective observational study of patients with mCRC who were treated with fruquintinib monotherapy. Patient demographics, disease characteristics, and treatment history were recorded at baseline (before fruquintinib administration). Dosage record, treatment outcome, and HRQoL, which was measured by EQ-5D-5L scale and then converted to UI score, were recorded in each cycle. The UI score was described in total patients. The changes of it from baseline at key point (first cycle of fruquintinib) and end point (last cycle of fruquintinib) between subgroups, including prior use of VEGF inhibitors, RAS mutation status, etc, were compared by T-test or Wilcoxon rank sum test. Median progression-free survival (mPFS) was calculated using Kaplan-Meier method. The medication compliance rate was summarized according to the dosage record. Results: Data of 70 patients from five centers between May 2021 and November 2022 were evaluated in this study. Fruquintinib was used in second line treatment in 15.7% cases (N = 11), and in third or later line in 84.3% cases (N = 59). The median UI scores of EQ-5D-5L were 0.89, 0.78 and 0.73 at baseline (N = 70), key point of follow-up (N = 62) and end point of follow-up (N = 23), respectively. There was no significant difference between subgroups in median UI score changes from baseline, such as whether VEGF inhibitors were used previously or not (at key point, -0.07 vs. -0.11, p = 0.82, at end point, -0.21 vs. -0.26, p = 0.27), and whether RAS mutation or not (at key point, -0.02 vs. -0.04, p = 0.79, at end point, -0.21 vs. –0.16, p = 0.62). The mPFS of the total population was 4.8 months (N = 69, 95%CI 3.5-6.2), numerically longer than mPFS in FRESCO and FRESCO-2 trials. The mean actual (actual doses per cycle/21 days) and prescribed daily doses were 4.46 mg and 4.65 mg for 21 out of 28 days per patient, respectively. The compliance rate (actual/prescribed) of fruquintinib was 95.91%. Conclusions: As with the previous study, fruquintinib showed a similar gradually declined trend in HRQoL, which may be associated with disease deterioration in heavily pretreated mCRC patients. Fruquintinib has prolonged mPFS with good compliance in clinical practice.

Role of social disparity in 30-day readmissions and healthcare utilization in patients with history of sickle cell crisis in United States: Cross-sectional analysis from US national database.

e18666 Background: Factors like age, mental status, spirituality, financial security, and clinic attendance affect hospital admissions/readmissions in sickle cell disease patients. To further understand the predisposing factors associated with increased readmissions in sickle cell disease patients, this study examined the relationship between readmission rates and socioeconomic status of Sickle cell patients in the US. Methods: All adult hospitalized patients in the Nationwide Readmission Database (NRD) for the year 2019 were captured. The sample population included all patients with primary diagnosis of Sickle cell crisis, identified using ICD-10 codes (International Classification of Diseases, tenth edition). We used the Wilcoxon rank sum test to compare continuous variables and chi square test for categorical variables. Predictors of readmission were analyzed using multivariate logistic regression models. We used StataCorp LLC MP4 17 version to perform statistical analysis. Results: The sample size included 48,715 patients admitted with sickle cell crisis, of which 55.12% were females and 44.88% were males. The mean age of presentation was 32.84 years. The rate of all cause 30-day readmission in patients admitted with Sickle cell crisis was 27.19%. The total hospital charges for these readmitted patients during the year 2019 was 507 million dollars and total length of stay was 69,418 days (about 190 years). The most common causes of readmissions were Sickle cell crisis including Acute chest syndrome and splenic sequestration crisis, followed by sepsis due to MRSA and femoral fractures. After adjusting for confounders on multivariate analysis, compared to patients belonging to income category 1 ( < $46,000), patients in category 2 ($46,000-$58,999) had 11% lower risk (p-value 0.018) and category 3 had 16% lower risk (p-value 0.008) of 30-day readmission. However, there was no increased risk of death based on socioeconomic status (OR 1.03, p-value 0.875). Conclusions: Our study concludes that socioeconomically deprived Sickle cell crisis patients are at higher risk of readmissions. Factors like poor living situation, lack of means for transportation, potential lower level of education leading to decreased medication compliance and clinic follow ups could be attributed to these findings. Interventions targeting this population can help reduce healthcare burden and patient morbidity significantly. [Table: see text]

Medication Compliance of Patients Attending a Pain Clinic at a Tertiary Hospital in Malaysia

Pain is a public health problem with profound physical, emotional, and societal costs. Conventional oral analgaesics are usually the first treatment, which is cost-effective and relatively safe. However, medication noncompliance is a serious healthcare concern. Medication noncompliance has remained a significant challenge despite considerable efforts to improve patient compliance. Therefore, a study was done to assess medication compliance at a Pain Clinic in a tertiary hospital in Malaysia. The study period was from December 2019 to January 2020. A total of 180 patients participated in the study. The study showed that pain clinic patients’ medication compliance was 65%. With the improvement of medication compliance, the quality of life of patients with pain can be improved.

Correlation of the Role of Drug Swallowing Supervisor (PMO) and Drug Side Effects with Medication Compliance in Elderly Pulmonary TB Patients

The 2019 World Health Organization notes that tuberculosis is a disease that is still a global concern. Indonesia has the 3rd highest number of cases after India and China. The target rate for medication adherence in Berau Regency, which is included in the elderly age group, has not been achieved due to the lack of PMO support and the side effects of the drugs experienced. The type of research used is analytical research which is carried out only through observation, without any intervention on the research subject. Statistical test results showed that there was no significant relationship between drug side effects and medication adherence with a pvalue of 0.273 > 0.05.

Colchicine usage for prevention of post atrial fibrillation ablation pericarditis in patients undergoing high-power short-duration ablation.

Radiofrequency ablation (RFA) for atrial fibrillation (AF) has been associated with variable incidence (0.88%-10%) of pericarditis manifested as chest pain, possibly more prevalent with the advent of high-power short-duration (HPSD) ablation. This has led to the widespread use of colchicine in preventative protocols for postablation pericarditis. However, the efficacy of preventative colchicine has not been validated yet. To evaluate the efficacy of a routine postoperative colchicine regimen (0.6 mg twice a day for 14 days post-AF ablation) for prevention of postablation pericarditis in patients undergoing HPSD ablation. We retrospectively evaluated consecutive single-operator HPSD AF ablation procedures at our institution from June 2019 to July 2022. A colchicine protocol was introduced in June 2021 for the prevention of postablation pericarditis. All ablations were performed with 50 watts. Patients were divided into colchicine and noncolchicine groups. We recorded incidence of postablation chest pain, emergency room (ER) visit for chest pain, pericardial effusion, pericardiocentesis, any ER visit, hospitalization, AF recurrence, and cardioversion for AF within the first 30 days following ablation. We also recorded colchicine-related side effects and medication compliance. Two hundred and ninety-four consecutive HPSD AF ablation patients were screened for the study. After implementing the prespecified exclusion criteria, a total of 205 patients were included in the final analysis, yielding 101 patients in the colchicine group and 104 patients in the noncolchicine group. Both groups were well-matched for demographic and procedural parameters. There was no significant difference in postablation chest pain (9.9% vs. 8.6%, p = .7), pericardial effusion (2.9% vs. 0.9%, p = .1), ER visits (11.9% vs. 12.5%, p = .2), 30-day hospitalization for AF recurrence (0.9% vs. 0.96%, p = .3), and 30-day need for cardioversion for AF (3.9% vs. 5.7%, p = .2). Fifteen (15) patients had severe colchicine-related diarrhea, out of which 12 discontinued it prematurely. There were no major procedural complications in either group. In this single-operator retrospective analysis, prophylactic colchicine was not associated with significant reduction in the incidence of postablation chest pain, pericarditis, 30 day hospitalization, ER visits, or AF recurrence or need of cardioversion within first 30 days after HPSD ablation for AF. However, its usage was associated with significant diarrhea. This study concludes no additional advantage of prophylactic use of colchicine after HPSD AF ablation.

The Importance of Medication Adherence in the Treatment of Actinic Keratosis: An Expert Consensus Panel

Background: Actinic keratosis (AK) is one of the most common dermatologic diagnoses. While there are several treatment options, many topical therapies have poor adherence due to duration of treatment and local skin reactions (LSRs).
 Objective: To review the available literature on the most commonly used patient-administered field-directed therapies for AK and create consensus statements on the role of medication adherence in improving AK outcomes.
 Methods: A literature search of PubMed was completed for English-language original research articles reporting efficacy, safety, and tolerability data for 5-FU, diclofenac gel, imiquimod cream, and tirbanibulin. Once the articles were selected, they were distributed to a panel consisting of seven dermatologists with extensive expertise in managing AKs. Each panelist reviewed the articles and assigned them a level of evidence based on Strength of Recommendation Taxonomy (SORT) criteria. The panelists then met to review and discuss the studies and created consensus statements on the management of AKs and the importance of medication compliance. A modified Delphi process was used to approve the adoption of each statement.
 Results: The literature search produced 1,326 articles that met search criteria. After screening these articles for relevance and applying the inclusion criteria, 17 articles were chosen to be reviewed by the panel and assigned a level of evidence based on SORT criteria. The panel then created six consensus statements that received a unanimous vote for adoption.
 Conclusion: While there are several options for the treatment of AK, there is little consensus on a standard of care. Clearance rates for the most common topical field therapies vary significantly but are also difficult to directly compare due to differences in methodology for measuring and assessing outcomes. Overall, it is clear that an efficacious, tolerable, and convenient treatment for AKs is critical to optimal adherence and management and, given the results of recent studies, tirbanibulin may be the best topical option for meeting these criteria.

Influencing factors of medication adherence in schizophrenic patients: a meta-analysis

Medication adherence of schizophrenic patients is a growing public health problem. We conducted a meta-analysis on the influencing factors of medication compliance in schizophrenic patients. We searched PubMed, Embase, Cochrane Library, and Web Of Science for relevant articles published up to December 22, 2022. Combined odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess influencing factors. Egger’s test, funnel plot, the trim and fill method, and meta-regression analysis were used to assess publication bias. A total of 20 articles were included in the analysis. Twenty influencing factors were divided into seven categories: drug factors (OR = 1.96, 95% CI: 1.48–2.59), problem behavior (OR = 1.77, 95% CI: 1.43–2.19), income and quality of life (OR = 1.23, 95% CI: 1.08–1.39), personal characteristics (OR = 1.21, 95% CI: 1.14–1.30), disease factors (OR = 1.14, 95% CI: 1.98–1.21), support level (OR = 0.54, 95% CI: 0.42–0.70), and positive attitude and behavior (OR = 0.52, 95% CI: 0.45–0.62). This meta-analysis found that drug factors, disease factors, problem behavior, low income and quality of life, and factors related to personal characteristics appear to be risk factors for medication adherence in people with schizophrenia. And support level, positive attitude and behavior appear to be protective factors.

Comparison of anti-hypertensive medication compliance between the tea tribe community and the non-tea tribe community seeking treatment from mobile medical units of Assam

BackgroundHypertension is the priority non-communicable disease, whose prevalence ranges from 10% to 55% and an estimated pooled prevalence of 16.1% within the tribal communities of India. Poor compliance to medication is a barrier to control hypertension levels and is an emerging public health challenge. Available evidence suggests varying prevalence of medication non-compliance in different parts of the country. To address the access challenge, National Health Mission supported Mobile Medical Units (MMUs) as one of its key strategies to deliver health services to the remote population. But the role of MMUs in medication compliance is underexplored. Paucity of medication compliance evidence is noted from the North-East states of India. ObjectivesTo assess medication compliance to oral medications among hypertensive Tea-tribe (TT) and Non-Tea-tribe (NTT) patients of the MMUs; Understand the ecological factors that may influence medication compliance. MethodsA comparative cross-sectional mixed-method study was conducted among the TT and NTT of Assam. A sample size of 196 was derived for the quantitative data and a random number of 6 per district was selected for qualitative data. Multi-stage Simple Random Sampling and Purposive sampling were used to recruit participants. ResultsAround 2(2%) of TT and 6(6.1%) of NTT reported moderate level of medication compliance. Medication compliance reported unequal distribution in the categories of education with minimum effect size. The qualitative findings reported patient and provider factors influencing medication compliance significantly. ConclusionEnsuring uninterrupted access to medication, patient and provider factors which affect medication compliance should be identified and addressed.

O009 Completion of supervised exercise therapy improves outcomes for patients with intermittent claudication: propensity score-matched analysis of 7-year outcomes

Abstract Introduction The goal of this study was to compare the long-term outcomes of patients with intermittent claudication (IC) who completed supervised exercise therapy (SET) versus patients who either declined or prematurely discontinued SET. Methods A retrospective, observational, single-centre cohort study of patients with IC referred to SET. Outcomes included progression to chronic limb-threatening ischemia (CLTI), revascularization requirement, and cardiovascular death.1:1 propensity score matching (PSM) using nearest-neighbour (caliper=0.2) was performed. Multivariate analysis (MVA) and logistic-regression (LR) were used to identify significant effect modifiers to guide PSM. Time-to-event data were analysed using Kaplan-Meier survival analysis. Results 241 patients were referred to SET between July 2015 and July 2016. Forty-nine patients completed SET and 192 patients did not. There was no significant difference in age, diabetes, smoking-cessation, and medication compliance between groups. After PSM, 49 patients who declined SET and 41 patients who completed SET were analysed. Progression to CLTI was significantly lower (10.2% vs 65.9%; p<0.001) in patients who completed SET. There was also a significant difference (p<0.001) in the median time to develop CLTI (1952 days [IQR 151;95% CI:1655 to 2249] vs 858 days [IQR 282; 95% CI:305 to 1411]). Revascularisation requirement: SET completion was associated with a significantly lower incidence of revascularisation (42.5% vs 57.5%; p=0.04) and a lower number of revascularization procedures SET(p<0.001). SET completion significantly delayed revascularization (1158 days [IQR 131;95% CI:931 to 1443] vs 326 days [IQR 38;95% CI:252 to 400]; p=0.03). There was no significant difference in the incidence (26% vs 35%; p=0.4) or time to cardiovascular death. Conclusion SET for claudication reduces requirement for future revascularisation by slowing disease progression.

Transferability Based on Drug Structure Similarity in the Automatic Classification of Noncompliant Drug Use on Social Media: Natural Language Processing Approach.

Medication noncompliance is a critical issue because of the increased number of drugs sold on the web. Web-based drug distribution is difficult to control, causing problems such as drug noncompliance and abuse. The existing medication compliance surveys lack completeness because it is impossible to cover patients who do not go to the hospital or provide accurate information to their doctors, so a social media-based approach is being explored to collect information about drug use. Social media data, which includes information on drug usage by users, can be used to detect drug abuse and medication compliance in patients. This study aimed to assess how the structural similarity of drugs affects the efficiency of machine learning models for text classification of drug noncompliance. This study analyzed 22,022 tweets about 20 different drugs. The tweets were labeled as either noncompliant use or mention, noncompliant sales, general use, or general mention. The study compares 2 methods for training machine learning models for text classification: single-sub-corpus transfer learning, in which a model is trained on tweets about a single drug and then tested on tweets about other drugs, and multi-sub-corpus incremental learning, in which models are trained on tweets about drugs in order of their structural similarity. The performance of a machine learning model trained on a single subcorpus (a data set of tweets about a specific category of drugs) was compared to the performance of a model trained on multiple subcorpora (data sets of tweets about multiple categories of drugs). The results showed that the performance of the model trained on a single subcorpus varied depending on the specific drug used for training. The Tanimoto similarity (a measure of the structural similarity between compounds) was weakly correlated with the classification results. The model trained by transfer learning a corpus of drugs with close structural similarity performed better than the model trained by randomly adding a subcorpus when the number of subcorpora was small. The results suggest that structural similarity improves the classification performance of messages about unknown drugs if the drugs in the training corpus are few. On the other hand, this indicates that there is little need to consider the influence of the Tanimoto structural similarity if a sufficient variety of drugs are ensured.

PO-02-204 COLCHICINE USAGE FOR PREVENTION OF POST ATRIAL FIBRILLATION ABLATION PERICARDITIS IN PATIENTS UNDERGOING HIGH POWER SHORT DURATION ABLATION

Radiofrequency ablation (RFA) for atrial fibrillation (AF) can be associated with up to 10% incidence of post-operative pericarditis, suspected to be more prevalent with the advent of high-power short duration (HPSD) ablation. This has led to widespread use of colchicine, an anti-inflammatory medication, for prevention of post-AF ablation pericarditis. However, the utility of preventative colchicine remains unproven. To evaluate the efficacy of a routine post-operative colchicine regimen for prevention of post-ablation pericarditis in patients (pts) undergoing HPSD ablation for AF. We retrospectively evaluated consecutive single-operator HPSD AF ablation procedures at our institution from June 2019 to July 2022. A colchicine protocol was introduced in June 2021 for prevention of post-ablation pericarditis. None of the pts before this date received preventative colchicine while all consecutive pts after this date received routine colchicine 0.6 mg twice daily for 14 days starting on the procedure day. Pts were divided into colchicine and non-colchicine groups (gps). We recorded the incidence of post ablation chest pain, emergency room (ER) visit for chest pain, pericardial effusion, pericardiocentesis, any ER visit, hospitalization, AF recurrence and cardioversion (CV) for AF within the first 30 days post-ablation. We also recorded colchicine-related side effects and medication compliance. Out of 225 consecutive procedures, 20 were excluded for lack of follow-up data, yielding 101 pts in the colchicine gp and 104 pts in the non-colchicine gp. Both gps were well-matched for demographic and procedural parameters (Table 1). There was no significant difference in post-ablation chest pain (9.9% vs 8.6%, p = 0.7), pericardial effusion (2.9% vs 0.9%, p = 0.1), ER visits (11.9% vs 12.5%, p = 0.2), 30-day hospitalization for AF recurrence (0.9% vs 0.96%,p = 0.3) and 30-day need for CV for AF (3.9 % vs 5.7%, p = 0.2) (Table 1). 15 pts had severe colchicine-related diarrhea, out of which 12 discontinued it prematurely (Figure 1). In this single-operator retrospective analysis, preventative colchicine was not associated with any significant reduction in the incidence of pericarditis, pericardial effusion, ER visits or AF recurrence within the first 30 days after HPSD ablation for AF. Colchicine usage was associated with significant diarrhea affecting patient compliance. Our findings argue against routine use of colchicine for prevention of post AF-ablation pericarditis.

Does a Lower Target of Postpartum Blood Pressure Reduce Readmission Rates in Patients With Hypertensive Disorders of Pregnancy? [ID: 1377089

INTRODUCTION: The classification of normal blood pressure in the general population, as determined by multiple organizations including the American Heart Association, American College of Cardiology, and National Institutes of Health, has been evolving. In the pregnant and postpartum population, the threshold of normal blood pressure is higher. Postpartum hypertension has been estimated to affect 20% of women and plays a large role in maternal readmissions. In those with hypertensive disorders of pregnancy, the target postpartum blood pressure should be reevaluated in light of the lower thresholds of the general population. METHODS: This study included pregnant patients with singleton fetuses and a diagnosis of chronic hypertension, gestational hypertension, preeclampsia, and eclampsia who delivered at Luminis Health Anne Arundel Medical Center from January 2019 to 2022. The primary outcome was hospital readmission for a hypertensive diagnosis or related sequelae within the first 30 days of delivery. This study was approved by IRB ID 1735193-1. RESULTS: Out of 1,433 patients with hypertensive disorders of pregnancy, 55 patients (3.8%) were readmitted because of hypertensive disorders or related complications. Patients with a maximum blood pressure after delivery of greater than or equal to 150/100 mm Hg were significantly more likely to be readmitted (odds ratio 1.99 [1.06, 3.75]). The maximum blood pressure on the day of discharge and oral antihypertensive initiation were not significantly associated with readmission. CONCLUSION: For postpartum patients with mild hypertension, a target blood pressure of below 150/100 mm Hg should be considered. Next steps include examining the effect of magnesium sulfate, furosemide, and discharge medication compliance in this population.

SCABIES TANISI OLAN BIREYLERDE İLAÇ UYUMU VE YAŞAM KALİTESİNİN BELİRLENMESİ

Objective: This study was conducted to determine the relationship between sociodemographic characteristics, skin quality of life and medical compliance in individuals diagnosed with scabies.
 Method: Patients diagnosed with scabies and called for follow-up after treatment were included in the study (87 people). A sociodemographic questionnaire and Skindex-16 Scale (Skindex-16) and Medication Adherence Report Scale were used in the study. The data were evaluated using the SPSS (Statistical Package for Social Sciences) package program and the level of significance was accepted as p

Breakthrough Psychosis and Long-Acting Injectable Antipsychotics

“Breakthrough” of psychosis despite good compliance of antipsychotics medication for a long time is a major obstacle to the treatment of schizophrenia, whether the mechanism is caused by dopamine hypersensitivity or insufficient dose of antipsychotics. Researchers advocating “Dopamine Supersensitivity Psychosis” (DSP) emphasize to avoid excessive inhibition of dopamine 2 receptors from the beginning of treatment. On the other hand, researchers advocating “Breakthrough psychosis on Antipsychotic Maintenance Medication” (BAMM) in which psychosis recurs due to insufficient medication despite continuous administration of antipsychotics without non-adherence argue that dose of antipsychotics should be increased to enhance therapeutic effect. In patients using long-acting antipsychotics injection (LAI), non-compliance can be ruled out. We believe that in treating non-affective psychosis, it is necessary to continuously maintain the lowest dose possible using the optimal dose considering the side effects of second-generation antipsychotics and the cycle and stage of psychosis, and the optimal formulation such as LAI.

Retrospective analyses of heartworm (Dirofilaria immitis) disease and ectoparasite preventive medication compliance in veterinary practices in the USA

BackgroundCompliance failure with administration of heartworm (HW) disease preventives has been reported as the main contributor to HW disease incidence in medicalized dogs. This study aimed to evaluate purchase compliance with different canine HW preventive products in the USA.MethodsAnonymized transaction data from clinics throughout the USA served as the basis for two retrospective analyses. We first examined the monthly equivalent doses of HW preventive purchases from clinics that had implemented extended-release moxidectin injectables ProHeart® 6 (PH6) and/or ProHeart® 12 (PH12) compared to clinics that prescribed monthly HW preventatives (MHWP) only. In the second analysis, the purchase compliance in practices that dispensed only flea and tick (FT) and HW products separately but did not dispense combination products (dual-therapy practices) was compared to the purchase compliance with the combination product Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets), purchased in clinics having implemented combination therapy in their formulary (combination-therapy practices). In both analyses, the numbers of monthly doses dispensed annually per dog were calculated.ResultsTransaction data from 3,539,990 dogs in 4615 practices were included in the first analysis. In dogs administered PH12 or PH6, the numbers of monthly equivalent doses were 12 and 8.1, respectively. In both clinic types, the average annual number of MHWP doses totaled 7.3. In the second analysis, a total of 919 practices were identified as combination-therapy practices and 434 as dual-therapy-only practices. A total of 246,654 dogs (160,854 dogs in dual-therapy practices and 85,800 dogs in combination-therapy practices) were included in the calculation of the average annual number of monthly doses, which totaled 6.8 (HW preventive products) and 4.4 (FT products) in dual-therapy practices compared to 7.2 months for both FT and HW preventives with Simparica Trio® across both practice types.ConclusionsThe injectable HW preventive PH12 is the only product that provides 12 months of heartworm disease prevention in a single veterinarian-administered injection. When choosing a monthly preventive, the combination therapy was associated with a greater purchase compliance compared with FT and HW products being dispensed separately.Graphical

Social support and medication compliance among myasthenia gravis patients in China: mediating role of mental health and self-efficacy

Social support and medication compliance among myasthenia gravis patients in China: mediating role of mental health and self-efficacy

The Relationship Between Medication Compliance And The Incidence Of Hypertension Crisis In RSUD. Haji Makassar

A hypertension crisis is an acute complication characterized by a severe increase in blood pressure, generally occurring ≥ 180/120 mmHg. Risk factors for hypertension generally occur due to a history of disease in the family, and age factors as factors that cannot be modified. An unhealthy lifestyle, including consuming alcohol, uncontrolled hypertension, or compliance to taking antihypertension drugs, is a modifiable factor but is often the cause of chronic hypertension to lead to a hypertension crisis. The purpose of this study is to determine the relationship between medication compliance to the incidence of hypertension crisis in hospitals. Makassar Hajj. This study used a cross-sectional research design with a total sampling technique of 34 respondents. This research was carried out in the treatment room of RSUD Haji Makassar. From the results of the study, it can be concluded that compliance to taking medication is associated with the incidence of emergency hypertension with a value of p = 0.008, OR = 112; the more obedient to taking antihypertension drugs, the less likely people with hypertension are to experience hypertension emergencies.

Analysis of Medication Compliance in Hypertension Patients at the Cempaka Putih District Health Center, Jakarta

Hypertension is characterized by an increase in blood pressure that is systolic (above 140 mmHg) and diastolic (above 90 mmHg), both of which are above the normal range. This can be seen in the medical records of the most hypertension sufferers from March to May as many as 758 respondents. This incident was caused by several things, one of which was non-compliance in taking drugs in Cempaka Putih Health Center patients. This study aims to determine the description of adherence to medication in hypertensive patients. This researcher uses quantitative with descriptive design. The number of samples in this study was 88 which were obtained through convenience sampling and data collection using a questionnaire. The results of this study showed that adherence to medication in hypertensive patients was obedient as many as 67 people (76.1%). Based on gender, namely female. Based on the elderly age above 56 years as many as 38 people (43.2%). Based on the level of education, namely high school graduates as many as 46 people (52.3%). Based on religion, namely Islam as many as 76 people (86.4%). Based on marital status that is married as many as 64 people (72.7%). Based on the work that is not working as many as 49 people (55.7%). Based on the distance of health services that is 1 km as many as 78 people (88.6%). Based on the length of suffering from hypertension that is > 5 years as many as 68 people (77.3%). Based on the number of drugs consumed, namely single as many as 88 people (100%). Based on the type of drug consumed, namely amlodipine as many as 82 people (93.2%).

Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors

Adjuvant endocrine therapy reduces the recurrence and mortality of early hormone receptor-positive breast cancer in both pre- and postmenopausal women. The aim of this study was to investigate adjuvant tamoxifen adherence and associated factors in breast cancer survivors. This descriptive, prospective study was conducted in 2019-2020 with the participation of 531 women who survived breast cancer and were under follow-up at the Senology Institute of a hospital in Istanbul. Inclusion criteria were having completed treatment for early hormone receptor-positive breast cancer, being prescribed tamoxifen, and being 18years or older. Data were collected using a patient information form and the Morisky Medication Adherence Scale-8 (MMAS-8). The mean age of the participants was 44.9 ± 6.5years, and the mean duration of tamoxifen use was 834.4 ± 685.7days. The women's mean MMAS-8 score was 6.86 ± 1.39. Medication adherence was significantly positively correlated with current age (p = 0.006) and age at diagnosis (p = 0.002). There was a statistically significant difference between tamoxifen adherence according to participants' employment status (p = 0.028), chronic disease status (p = 0.018), loss of libido (p = 0.012), treatment-related changes in mood changes (p = 0.004), and having negative effects affecting daily life (p < 0.001). Overall, breast cancer survivors in this study reported moderate adherence to tamoxifen. The women's individual characteristics and the adverse effects of treatment influenced medication adherence. Healthcare professionals can help increase adherence to this treatment, which reduces the risk of mortality, by explaining the importance of the medication, identifying and eliminating barriers to adherence, and informing women about evidence-based interventions to increase medication compliance.

Does circle priming improve smart infusion pump and electronic health record interoperability for chemotherapy in a pediatric hematology/oncology setting?

The objective of this project was to assess the percentage of interoperability compliance within our pediatric hematology/oncology patient care areas for intravenous chemotherapy medications before and after the implementation of circle priming. We conducted a retrospective quality improvement project at an inpatient pediatric hematology/oncology floor and outpatient pediatric infusion center before and after implementation of circle priming. There was a statistically significant increase in percent interoperability compliance for the inpatient pediatric hematology/oncology floor from 4.1% prior to implementation of circle priming to 35.6% after (odds ratio 13.1 (95% CI, 3.96-43.1), p < 0.001), as well as for the outpatient pediatric infusion center from 18.5% to 47.3%, respectively (odds ratio 3.9 (95% CI, 2.7-5.9), p < 0.001). Implementation of circle priming has significantly increased the percentage of interoperability compliance for intravenous chemotherapy medications in our pediatric hematology/oncology patient care areas.